You are here: Industry Insights > Drug

News List

Late-stage pipeline drugs could compete with only treatment for SMA europeanpharmaceuticalreview
April 10, 2019
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise…
No association found between trazodone and reduced risk of dementia europeanpharmaceuticalreview
April 10, 2019
The antidepressant drug, trazodone, taken for anxiety and depression, has been found not to be linked to a reduced risk of dementia…
NEWS FDA finds another carcinogenic impurity in ARB blood pressure drug europeanpharmaceuticalreview
April 10, 2019
FDA is ‘deeply concerned’ about a third type of nitrosamine impurity detected in angiotensin II receptor blocker (ARB) medicines…
Diversifying drug development with a metal catalyst europeanpharmaceuticalreview
April 10, 2019
Researchers have outlined a method of formulating drug-like aliphatic and aromatic carbon-hydrogen scaffolds into drugs using a metal catalyst…
Six new licensing deals for drug and gene therapy development firm europeanpharmaceuticalreview
April 10, 2019
Oxford Genetics has won six new licensing deals for its scalable drug and gene therapy manufacturing in the synthetic biology sector…
NICE recommends BMS’ Opdivo-Yervoy combination for RCC pharmaceutical-technology
April 09, 2019
Bristol-Myers Squibb (BMS) has announced that the National Institute of Health and Care Excellence (NICE) has recommends Opdivo (nivolumab) and...
Gilead submits sNDA to FDA to expand HIV label for Descovy pharmaceutical-technology
April 09, 2019
Gilead submits sNDA to FDA to expand HIV label for Descovy
FDA-approved drug effectively treats rare chronic immune disorder firstwordpharma
April 04, 2019
A drug approved to treat a severe form of asthma dramatically improved the health of people with rare chronic immune disorders ……
Pain intensifies for AbbVie as it slashes 178 jobs from Stemcentrx fiercebiotech
March 29, 2019
It was a $6 billion deal that was meant to help bolster AbbVie’s pipeline and help wean the biopharma off its Humira reliance, but Stemcentrx has proven to be a major thorn in its side. Now, the time has come to start digging it out.
Alembic Pharma raises Rs 150 crore via NCDs expressbpd
March 20, 2019
Drug firm Alembic Pharmaceuticals has said it has raised Rs 150 crore through the allotment of non-convertible debentures (NCDs) on private placement basis. These NCDs carry a coupon rate of 8.37 per cent per annum and are proposed to be listed on NSE.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 49 50 Next page